AbbVie completed the acquisition of Nimble Therapeutics for $200m.

AbbVie, a pharmaceutical company that discovers, develops, and markets medicines, completed the acquisition of Nimble Therapeutics, a biotechnology company, for $200m. "With the acquisition now complete, we are excited to expand our immunology pipeline to include Nimble's novel oral peptide assets and look forward to integrating this proprietary technology into our R&D capabilities. We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases," Jonathon Sedgwick, AbbVie senior vice president and global head of discovery research.